Supporter News
ASH 2025
In December 2025, ALAN’s team actively participated in the American Society of Hematology (ASH) Annual Meeting, the world’s premier event for hematology research and clinical advancements. Our presence at ASH 2025 strengthened ALAN’s role as a global advocate for people living with adult leukemias and ensured that the patient perspective remained central in discussions shaping…
Variances In Patient-Reported Experiences with Shared Decision-Making By Biological Sex in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) – An Analysis from the Lymphoma Coalition 2024 Global Patient Survey on Lymphomas And CLL
TopicsAll ResearchCommunication & Decision-MakingDoctor–Patient CommunicationShared Decision-MakingAccess to CareAgeBarriers to TreatmentCOVIDPsychosocial & Quality of LifePsychosocialSurvivorshipQuality of LifeTreatment & Side EffectsCAR-TClinical TrialsFatigueSide EffectsTreatmentSubtype-SpecificCLLHodgkin LymphomaRelapse/RefractoryHealth Literacy Variances In Patient-Reported Experiences with Shared Decision-MakingDownload Variances in Patient-Reported Experiences with Shared Decision-Making by Biological Sex in Patients with DLBCL – An Analysis from the Lymphoma Coalition 2024 Global Patient Survey…
Evolving Patient-Reported Value of Treatment Attributes in Follicular Lymphoma: Insights from the Lymphoma Coalition 2024 Global Patient Survey on Lymphomas And CLL
TopicsAll ResearchCommunication & Decision-MakingDoctor–Patient CommunicationShared Decision-MakingAccess to CareAgeBarriers to TreatmentCOVIDPsychosocial & Quality of LifePsychosocialSurvivorshipQuality of LifeTreatment & Side EffectsCAR-TClinical TrialsFatigueSide EffectsTreatmentSubtype-SpecificCLLHodgkin LymphomaRelapse/RefractoryHealth Literacy Evolving Patient-Reported Value of Treatment Attributes in Follicular Lymphoma Insights From the Lymphoma Coalition 2024 GPSDownload Evolving Patient-Reported Value of Treatment Attributes in Follicular Lymphoma: Insights From the Lymphoma Coalition 2024 Global…
Highlights from ASH 2025-Update in AML
The following summaries highlight key findings from research posters presented at the 67th ASH Annual Meeting, showcasing new developments in oral maintenance therapies for acute myeloid leukemia (AML). All abstracts can be accessed here –> Abstracts ASH 2025 Selected abstracts –> Selected abstracts AML Updated ASH Clinical Practice Guidelines on AML in Older Adults Updated…
Highlights from ASH 2025 – Update in ALL
The following summaries highlight key findings from research posters presented at the 67th ASH Annual Meeting, showcasing new developments in oral maintenance therapies for acute myeloid leukemia (ALL). All abstracts can be accessed here –> Abstracts ASH 2025 Selected abstracts –> Selected abstracts ALL Advances in treatment for B–cell acute lymphoblastic leukemia (B‑ALL) How treatment…
Lymphoma Coalition Announces Three New Board Directors to Drive 2025-2030 Strategic Vision
December 4, 2025 – Lymphoma Coalition (LC), a global network dedicated to improving outcomes for people living with lymphoma, is pleased to announce the appointment of three new members to its Board of Directors: Dr. Clara Chamba (Tanzania), Pete DeNardis (USA) and Meghan Gutierrez (USA). These leaders join the Board at a pivotal time, bringing essential expertise in policy, diagnostics, research, and…
Spotlight on ALAN members
In 2025, with ALAN support, some of our members have been able to start and/or complete projects which benefit acute leukemia patients and their families. We are very grateful that our support could contribute to make these projects happen. Acute Leukemia Patient Advocacy Group Thailand Project Title: Strength in Knowledge, Hope in Action: Empowering Patients…
ALAN Releases Landmark Study on the Burden Faced by Informal Carers of People Living with Acute Leukemia
The Acute Leukemia Advocates Network (ALAN) has published a groundbreaking qualitative study exploring the lived experiences of informal carers across six countries. This first-of-its-kind report sheds light on the profound social, economic, mental, and physical challenges faced by those who provide unpaid care to someone living with acute leukemia. Understanding the Impact of Caring for…
Capturing the Lived Experiences of Informal Care in Acute Leukemia
Acute leukemia imposes a heavy toll on both patients and carers Acute leukemia is a group of aggressive cancers that affect the blood and bone marrow. Acute leukemia progresses rapidly, requires intensive treatment and often leaves patients heavily dependent on family or friends (unpaid, informal carers) for day-to-day support. There is a lack of evidence…
Patient preferences for treatment in relapsed/refractory acute leukemia
When acute leukemia relapses, treatment decisions can be complex. Patients may face trade-offs between survival benefits, side effects and how treatment is delivered. This study asked people with acute leukemia across five countries what matters most to them when making these choices. How did we do it? We surveyed 267 patients in the UK, USA,…
